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The Reverse Protraction Factor in the Induction of Bone Sarcomas 
in Radium-224 Patients 
D . CHMELEVSKY , * H . SPIESS,! C. W . MAYS, 4 ^ 1 A N D A . M . KELLERER§ 
* Institut für Strahlenschutz der GSF, Ingolstadt er Landsir. I, D-8042 Neuherberg, Federal Republic of Germany; t Kinderpoliklinik, Universität 
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D-8700 Würzburg, Federal Republic of Germany 
CHMELEVSKY, D., SPIESS, H. , MAYS, C. W., AND KELLERER, 
A. M . The Reverse Protraction Factor in the Induction of Bone 
Sarcomas in Radium-224 Patients. Radiat. Res. 124, S69-S79 
(1990) . 
More than 50 bone sarcomas have occurred among a collec-
tive of about 800 patients who had been injected in Germany 
after Wor ld War I I wi th large activities of radium-224 for the 
intended treatment of bone tuberculosis and ankylosing spondy-
litis. In an earlier analysis [ H . Spiess and C. W. Mays, in Radia-
tion Carcinogenesis. (C. L. Sanders et aL, Eds.) pp. 437-450. 
USAEC Symposium Series 29, CONF-720505, 1973] it was 
concluded that, at equal mean absorbed doses in the skeleton, 
patients with longer exposure time had a higher incidence of 
bone sarcomas. The previous analysis was based on approxima-
tions; in particular, i t did not account for the varying times at 
risk of the individual patients. In view of the implications of a 
reverse protraction factor for basic considerations in radiation 
protection, the need was therefore felt to reevaluate the data 
from the continued follow-up by more rigorous statistical meth-
ods. A first step of the analysis demonstrates the existence of the 
reverse dose-rate effect in terms of a suitably constructed rank-
order test. In a second step of the analysis it is concluded that 
the data are consistent with a linear no-threshold dose depen-
dence under the condit ion o f constant exposure t ime, while 
there is a steeper than linear dependence on dose when the expo-
sure times increase proportionally to dose. A maximum likel i-
hood fit of the data is then performed in terms of a proportional 
hazards model that includes the individual parameters, dose, 
treatment duration, and age at treatment. The fit indicates pro-
portionality of the tumor rates to mean skeletal dose with an 
added factor (1 + 0 . 18 - r ) , where t is the treatment time in 
months. This indicates that a protraction of the injections over 
15 months instead of 5 months doubles the risk of bone sar-
coma. © 1990 Academic Press, Inc. 
INTRODUCTION 
The follow-up of patients who were injected with high 
doses of the short-lived a emitter 2 2 4 Ra in Germany from 
1 Deceased August 3, 1989. 
1944 to about 1964 continues to provide important infor-
mation on various late effects, such as cataracts, tooth 
breakage, or severe kidney diseases (1-3). There are also 
recent indications of increased incidences of breast and 
liver tumors (4). 
The bone sarcomas, which were the most dramatic and a 
most severe consequence, began to appear only a few years 
after the treatment; their increased risk appears to be elimi-
nated by now. It must be assumed that all 56 reported bone 
sarcomas were due to the 2 2 4 Ra injections. On the basis of 
population statistics in the Federal Republic of Germany, 
less than one spontaneous bone sarcoma would have been 
expected during the follow-up period among the patients, 
and there is no evidence that the rate of bone sarcomas is 
increased due to ankylosing spondylitis or bone tuber-
culosis, the two illnesses that prompted the treatment 
with 2 2 4 Ra. 
The cohort of patients comprises a broad range of ages at 
treatment and of injected doses. Furthermore, there is con-
siderable variation in the temporal distribution of the series 
of injections, from short durations up to many months. The 
nearly complete follow-up allows, therefore, a detailed anal-
ysis of the time and dose dependence of the 2 2 4Ra-induced 
bone sarcomas, but beyond this it permits conclusions on 
the possible influence of added factors such as the age at 
treatment or the duration of treatment. The focus of the 
present analysis is on this latter factor. 
The short-lived 2 2 4 Ra accumulates on bone surfaces. The 
mean absorbed dose in the skeleton for juveniles under 16 
years of age at injection was estimated (5) to be 0.16 
Gy/MBq (= 0.6 rad/VCi) injected activity per kilogram 
body weight. For juveniles between 16 and 20 years of age 
at injection a conversion factor of 0.11 Gy/MBq was ob-
tained, and for adults 0.054 Gy / MBq. The subsequent anal-
ysis employs mean skeletal doses according to these values. 
To avoid meaningless discontinuities at ages 16 and 20, a 
linear interpolation is used for this age group between the 
value 0.16 Gy/MBq for 16 years and 0.054 Gy/MBq for 20 
years. This is a slight deviation from earlier analyses where 
S69 0033-7587/90 $3.00 
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the simpler step function was employed, but it affects only 
7% of all patients and only 3% of those with bone tumors. 
Al l subsequent computations were run with and without 
the modification; this did not indicate that the modification 
was critical for any of the conclusions. The mean skeletal 
absorbed dose according to the above assumptions is used 
as reference quantity in the subsequent considerations, and 
it is simply termed dose wherever the meaning is clear from 
the context. 
A central finding of the epidemiological study was the 
occurrence of bone sarcomas in a temporal wave after treat-
ment which reached a maximum 8 years after first injection 
and continued, at decreasing rates, to about 30 years after 
treatment. A linear dose dependence had first been esti-
mated for the probability of the occurrence of a bone sar-
coma with the coefficient 0.018 per Gy (6, 7). A later more 
detailed analysis in terms of the proportional hazards 
model has indicated a linear-quadratic dose dependence 
(<S, 9). In this dependence the linear term was 0.085 per Gy, 
i.e., it was reduced by a factor of 2; the quadratic compo-
nent corresponded to the increased bone-sarcoma frequen-
cies per unit dose in the patients subjected to higher doses. 
The inferred dose-response relationship may, of course, 
be codetermined by possible confounding factors such as 
sex, age at treatment, original illness, and temporal distri-
bution of the injections, and these factors may therefore be 
considered in any quantitative analysis. 
A previous analysis (8) led to the conclusion that neither 
sex nor original illness plays a noticeable role; both factors 
can consequently be disregarded in the analysis of time and 
dose dependences. 
Age at treatment, too, was not found to influence the 
bone-tumor response; the analysis in terms of a propor-
tional hazards model gave substantially the same temporal 
dependence and the same absolute frequencies at a given 
mean skeletal dose in the adult and juvenile cohorts. How-
ever, the age dependence of the dose conversion factors is 
somewhat uncertain, and this implies some uncertainty 
also in the dose-effect relationship, because the patients 
with higher dose were on average considerably younger. 
A substantial correlation exists between mean skeletal 
dose and duration of treatment (see Fig. 2). The duration 
of treatment increases somewhat less than proportionally to 
injected activity, and the enhanced durations of exposure at 
higher doses could be fully or partially responsible for the 
deviation of the dose-effect relationship from linearity that 
was inferred in the earlier analysis (8, 9). This possibility 
wil l be examined here. Spiess and Mays studied the prob-
lem earlier (5) , and they concluded that the incidence of 
bone sarcomas is increased at longer irradiation times. Such 
a 'reverse' protraction factor was suggested in earlier inves-
tigations in mice (70). While the findings in animals have 
been confirmed, at least at high doses, it is more difficult to 
quantify, or even to establish rigorously, a protraction fac-
tor in the patients injected with 2 2 4 Ra. The finding of a 
protraction factor, and especially a reverse protraction fac-
tor, for a stochastic effect of a rays on humans, on the other 
hand, has considerable implications for the basic principles 
of radiation protection, and this has led us to reexamine the 
earlier conclusions by methods which are not based on an 
assumed linearity of the dose-effect relationship and which 
take into account the different times at risk of the individ-
ual patients. 
SYNOPSIS OF THE DATA 
The data are summarized in Table I . Additional details 
are given in several earlier reports (1 -3 ) . The classification 
in the table follows the one adopted by Spiess and Mays. 
Among 900 patients, 89 with unknown dose or injection 
span (among them 10 with bone sarcoma) were excluded 
from the analysis. The patients who incurred a bone tumor 
had a median further survival less than 4 years, but of the 44 
patients with known dose and injection span who incurred 
bone sarcomas, one developed a second bone sarcoma 16 
years later. The inclusion of this additional tumor has no 
substantial influence on the results, and it is therefore ig-
nored in the analysis. 
The majority of the intravenous injections of 2 2 4 Ra were 
given at weekly intervals, with the total injection span rang-
ing from a few weeks to a maximum of 2.5 years. In a few 
cases only a single injection was given. The injection span is 
taken to be the time in months between the first and the last 
injection. For the few patients (four juveniles and eight 
adults) who had received two or more series of injections, 
the total injection span was set equal to the sum of the 
individual spans. To simplify the data, the injection spans 
were rounded up to integer numbers of months. The short 
half-life of 2 2 4 Ra of a few days makes the effective exposure 
time of the skeleton approximately equal to the injection 
span. 
The subsequent analysis is, when not otherwise specified, 
performed in terms of the variable injection span, r. This 
quantity appears more suitable than related variables, such 
as the ratio of mean skeletal dose to injection span, D/r, 
because it wi l l remain unaffected by possible future dosi-
metric revisions. 
Figures 1 and 2 give the distribution of the patients with 
and without bone sarcomas in mean skeletal dose vs age at 
treatment and vs injection span. Figure 1 serves merely to 
illustrate the basic data. Figure 2 is relevant to the analysis 
of the dependence of the bone-sarcoma incidence on dose 
and injection span. Considering narrow bands in treatment 
time, one recognizes readily the trend of the heavy dots to 
occur at relatively higher doses than the light dots. Con-
versely one would recognize a higher probability of bone 
sarcomas at longer treatment durations by an upward verti-
cal shift of the heavy dots relative to the light dots; however, 
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Synopsis of Data through 1987 
Mean age* 
Number Mean Mean 
Number of with bone At first At last At bone skeletal dose treatment span 
patients sarcoma injection follow-up sarcoma (Gy) a (months)" 
A l l adults 587 11 38.7(10.8) 62.0(11.5) 47.5(11.3) 2.12(1.50) 5.5 (4.0) 
Ankylosing spondylitis 341 5 41.2 (9.5) 63.8(10.0) 58.2 (4.4) 1.44(1.00) 3.6 (2.7) 
Tuberculosis 205 6 33.5(10.7) 59.0(12.7) 38.7 (6.6) 3.31 (2.25) 8.8 (7.0) 
Other 41 0 43.9(12.2) 61.4(13.8) — ( - ) 1.83 (1.24) 4.3 (3.4) 
Male adults 435 9 39.3(10.2) 62.6(10.9) 49.2(11.5) 1.87 (1.53) 5.0 (4.7) 
Ankylosing spondylitis 321 5 41.1 (9.5) 63.8(10.1) 58.2 (4.4) 1.42(1.00) 3.6 (2.7) 
Tuberculosis 96 4 32.9(9.9) 59.4(11.9) 38.0 (6.8) 3.32 (2.05) 9.5 (6.9) 
Other 18 0 41.1 (10.3) 58.8(14.3) - ( - ) 2.10(1.37) 5.4(3.6) 
Female adults 152 2 36.9(12.3) 60.2(13.1) 40.0 (6.0) 2.83 (2.24) 6.8 (6.5) 
Ankylosing spondylitis 20 0 41.3(9.7) 64.5 (8.7) - ( - ) 1.68 (0.97) 3.4(1.9) 
Tuberculosis 109 2 34.1 (11.3) 58.7 (13.4) 40.0 (6.0) 3.29 (2.41) 8.2(7.1) 
Other 23 0 46.2(13.1) 63.5 (13.1) - ( - ) 1.62(1.09) 3.3 (2.9) 
Children and juveniles 198 33 11.6(5.3) 38.5(13.1) 19.9 (5.8) 10.71 (8.78) 10.9(8.7) 
Boys 102 16 11.6(5.3) 39.2(12.9) 22.2 (6.4) 11.57 (9.68) 11.5(9.1) 
Girls 96 17 11.7(5.3) 37.6(13.1) 17.7(4.1) 9.81 (7.62) 10.4 (8.2) 
Note. Number of patients included in analysis, 785. Number of patients with bone sarcoma, 44 (double: 1). Number of patients excluded from analysis 
because of missing dose or injection duration, 89 (10 with bone sarcoma (double: 1); lost to follow-up, 26. 
a Mean and (standard deviation). 
such a shift, i f present, is not evident, and its ident i f icat ion 
therefore requires a statistical analysis. 
The numer ica l evaluat ion can be based on a m a x i m u m 
l ike l ihood fit to appropriate ly chosen analyt ical expressions 
for the dependence o f bone-sarcoma inc idence o n dose, 
t reatment dura t i on , and t i m e after t reatment . However, i t 
is desirable to precede this evaluat ion by a nonparametr ic 
examinat ion o f the existence o f a t ime factor. The nonpara-
metr ic evaluat ion is free f r om bias that may result f r om the 
choice o f ana ly t i ca l expressions for the dependence on 
dose, dura t i on o f t reatment , and t ime after treatment, and 
i t w i l l prov ide guidance for the subsequent choice o f suit-
able analyt ical expressions. 
T H E PRESENCE OF A PROTRACT ION FACTOR 
Analysis in Terms of Dose Bands 
Spiess and Mays have in the ir earlier analysis ( 5 ) exam-
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FIG. 1. Scatter diagram of age at treatment versus mean skeletal dose. 
Each patient is represented by a dot. A patient who, at later age, developed 
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FIG. 2. Scatter diagram of treatment duration versus mean skeletal 
dose. Each patient is represented by a dot. A patient who, at later age, 
developed a bone sarcoma is represented by a heavy dot. 
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Results of the Rank-Order Test 
No. of patients Level of 
(No. of bone Mean rank" significance* 
sarcomas) (SD) (one-sided test) 
Ranking in treatment duration in dose bands of width ±25% 
Al l patients 785 (44) 0.586 (0.043) 0.02 
Juveniles 198 (33) 0.572 (0.050) 0.07 
Adults 587 (11) 0.564 (0.087) 0.2 
Ranking in age at injection in dose bands of width ±25% 
Al l patients 0.464 (0.043) 0.2 
Juveniles 0.433 (0.050) 0.08 
Adults 0.548 (0.087) 0.3 
a The values in brackets are the standard deviations of the mean rank 
from 0.5 under the null hypothesis that the ranks are equidistributed. 
b Against the null hypothesis that the ranks in treatment duration or in 
age are uniformly distributed. 
were given on the incidence of bone sarcomas. They di-
vided the entire cohort of patients into nine dose groups 
and divided each of the groups equally into the patients 
below and above the median treatment span. An excess of 
bone-sarcoma cases was then found among the patients 
with longer treatment spans although the average doses 
were about the same in the group of patients with longer 
and shorter treatment spans. This was a valid approach, but 
it contained features that can be improved. The particular 
importance of this singular data set and the possible impl i -
cations of a reverse protraction effect for radiation protec-
tion therefore suggested an extension of the analysis. 
The earlier treatment did not account for the different 
times at risk of the individual patients. That this omission 
could introduce a bias is readily understood. There is, for 
example, the possibility that the patients with extended 
treatment span survived on average longer than patients 
with the same mean skeletal dose but shorter treatment 
span. Their increased time at risk could then have been the 
reason for a higher number of bone sarcomas. This particu-
lar explanation is not suggested by the data; but there could 
be similar influences, and this necessitates an analysis that 
corrects for different times at risk. 
In the present approach we use the same principle as in 
the earlier analysis, i.e. the durations of treatment for the 
patients with bone sarcomas are compared to the durations 
of treatment in other patients with equal or similar doses. 
However, the approach is modified insofar as each patient 
with bone sarcoma is compared only to patients who were 
at risk for, at least, a duration after treatment that equals the 
time to the diagnosis of the bone sarcoma. A second modifi-
cation is introduced by comparing the duration of treat-
ment of the patient with bone sarcoma not merely with the 
median duration for the comparison patients, but by using 
the rank among all durations as a more precise measure. 
The third modification relates to the use of dose groups in 
the earlier analysis. The choice of separate dose classes was 
somewhat arbitrary, and a more general procedure is ob-
tained by comparing each patient with bone sarcoma with 
those patients whose estimated doses differ by less than 
±25%. This means that every patient is ranked in his own 
dose band with regard to treatment span, against all other 
patients who are in this dose band and who had been at risk 
for at least the same time. We call this the comparison 
group, and one must note that each patient with bone sar-
coma has his own comparison group, depending not only 
on his dose but also on the time after treatment when his 
tumor occurred. 
As a further improvement a correction is employed in 
this analysis in establishing the normalized ranks. Since 
each bone-sarcoma patient is ranked against patients with 
somewhat different doses, a linear regression is performed 
between the logarithms of the dose and the logarithms of 
the duration of treatment within the dose band. The regres-
sion coefficient is then utilized to scale the durations of 
treatment in the comparison group so that they correspond 
to the dose of the patient with bone sarcoma. 
Under the null hypothesis that the treatment span has, at 
equal doses, no effect on the frequency of bone sarcomas, 
there would be no tendency that the tumor occurred prefer-
entially among the patients with either longer or shorter 
treatment spans. The rank would therefore be expected to 
be equally distributed between 1 and the number, N, of 
patients in the comparison group. It is convenient to use, 
instead of the absolute rank, A?, the relative rank, 
r = (n-0.5)/N. (1) 
The lowest and the highest possible ranks are then 0.5/N 
and (N - 0.5)/N. Under the null hypothesis the relative 
ranks are uniformly distributed among the possible values 
with mean 0.5 and, as can be readily shown (see Appen-
dix) , with variance a2 = (1 - 1 /N2)/\2. The mean relative 
rank for a group of K patients with bone tumors is then, 
under the null hypothesis, distributed with mean 0.5 and 
variance 
where is the number of patients in the comparison group 
of patient k with bone sarcoma. The values Nk vary between 
7 and 120, and the term \/N\ in Eq. (2) is thus always 
small, a1 is consequently close to 1/12- AT. Since K equals 
44, the distribution is very nearly Gaussian. 
A mean rank larger than 0.5 for the patients with bone 
sarcoma indicates enhanced risks for longer treatment dura-
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FIG. 3. The relative ranks in treatment duration for the 44 patients 
with bone sarcomas. The results are obtained i f each patient with bone 
sarcoma is ranked among patients whose doses do not differ by more than 
±25%. The mean relative rank is 0.586. The filled dots refer to juvenile 
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FIG. 4. Sum distributions of the relative ranks with regard to treat-
ment duration. The results are obtained i f each patient with bone sarcoma 
is ranked among patients with dose differences up to ±10%, ±20%, or 
±30%. 
tions at equal doses. In fact, one finds that the average rela-
tive rank is 0.586 for the 44 patients with bone sarcomas. 
With a standard deviation a = 0.043 under the null hypoth-
esis one obtains a one-sided level of significance of 0.023 
(see Table I I ) . 
Figure 3 gives the results in explicit form by showing the 
relative ranks for the patients with bone sarcoma and their 
doses. Especially at low doses, one recognizes a tendency of 
the ranks to be high, this suggests a reverse dose-rate effect, 
i.e., a more frequent occurrence of the bone tumors in pa-
tients with longer treatment spans, even at low doses. This 
observation at low doses, however, is not significant by it-
self; when the test is performed for the adult patients only, 
one obtains an elevated mean rank that exceeds the expec-
tation only on a one-sided level of 0.25. For the juvenile 
patients alone the significance level is 0.07. 
It is found that the width of the dose bands is fairly uncri-
tical. Between values of ±10% to ±30% the resulting mean 
ranks remain substantially unchanged. Figure 4 illustrates 
this point in terms of the sum distribution of the ranks; it 
gives a superposition of the distributions that result i f the 
values ±10%, ±20%, or ±30% are chosen. 
Age as a Possible Confonnder 
While duration of treatment is strongly correlated with 
dose, there is also a (negative) correlation of dose with age. 
It is therefore of interest to see whether the bone-sarcoma 
rates are, at a specified dose, dependent on age. The same 
type of analysis was consequently performed with regard 
not to the duration of treatment but to age at treatment. 
Figures 5 and 6 give the results obtained from the rank test. 
There is a slight indication of higher bone-sarcoma rates at 
equal doses for lower ages at treatment, but the difference is 
not significant. 
If, on the other hand, one considers juveniles only, i.e., i f 
all those who were older than 20 at the time of the treat-
ment are removed from the analysis, one obtains a some-
what stronger indication of enhanced bone-sarcoma rates 
at equal doses for the younger ages. However, this result, 
too, does not reach significance, even on the one-sided 5% 
level. The apparent trend can, of course, be a result of the 
rather crude dose factors which have been discussed in the 
introduction and which may underestimate somewhat the 
doses for the younger children. 
In view of the indication that there may be some depen-
dence—artificial or real—of the bone-sarcoma incidences 
on age at treatment, one must ask whether this could partly 
account for the apparent dependence on the duration of 
treatment. I f there were a negative correlation at specified 
doses between duration of treatment and age, one could not 
readily distinguish whether the enhanced bone-sarcoma 
A L L BONE S A R C O M A S 
0.5 5 50 
MEAN S K E L E T A L DOSE / Cy 
FIG. 5. The relative ranks in age at treatment that result i f each patient 
with bone sarcoma is ranked among patients whose doses do not differ by 
more than ±25%. The mean relative rank is 0.464. The filled dots refer to 
juvenile patients who developed a bone sarcoma, the open dots to adult 
patients. 
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FIG. 6. Sum distribution of the relative ranks with regard to age at 
treatment. The results are obtained i f each bone sarcoma patient is ranked 
among patients with dose differences up to ±10%, ±20%, or ±30%. 
rates are due to the younger ages or the longer t reatment 
t imes. 
For this reason Fig. 7 gives for al l patients and for the 
juven i l es the co r re la t i on o f the re lat ive ranks, at equal 
doses, i n treatment dura t i on and i n age at t reatment. There 
is no evident corre lat ion, and the Spearman corre lat ion co-
efficient o f the relative ranks i n dura t i on and i n age has 
even slightly positive values. Th i s strengthens the conc lu-
sions that the reverse pro t rac t i on effect is real. 
The results ob ta ined w i t h the rank-o rde r test d e m o n -
strate that the longer t reatment spans are, at equal mean 
skeletal doses, associated w i t h higher incidences o f bone 
sarcomas. The next step i n the analysis is then t o ask 
whether the earlier finding (8, 9) o f a l inear-quadrat ic dose 
re la t i onsh ip was a mere re f lect ion o f the higher average 
treatment spans at higher doses, and whether the dose rela-
t i onsh ip wou ld be l inear, i f al l exposures had the same dura-
t i o n . 
E X P L O R A T I O N OF T H E N A T U R E O F T H E 
D E P E N D E N C E O N DOSE A N D T R E A T M E N T 
D U R A T I O N 
The quant i ta t i ve analysis o f the dependence o f the bone-
sarcoma incidence on dose and dura t i on o f t r ea tment can 
be faci l i tated by a p re l im inary step that provides guidance 
on the general nature o f the dependence. For this purpose, 
too, one can use the nonparametr ic approach. 
T w o simple possibilities w i l l be explored. One is dose 
propor t i ona l i t y at equal t reatment durat ions, the second is 
dose p ropor t i ona l i t y at " constant dose ra te , " i.e., at injec-
t i o n spans that are p ropor t i ona l t o mean skeletal dose. 
The two assumptions are examined i n terms o f a r ank -
order test that is s imi lar to the one appl ied i n the preceding 
section, bu t that compares patients i n classes o f the same 
treatment dura t i on , r , or o f the same "dose rates," D/r. 
Consider first the assumpt ion that dose p ropo r t i ona l i t y 
applies at constant values, r , o f the t reatment d u r a t i o n . I n a 
group o f patients w i t h equal r b u t different doses, the bone 
sarcomas should then be d is t r ibuted among the patients 
w i t h probabi l i t ies p ropor t i ona l to the i r doses. T o examine 
this possibi l i ty the patients o f the group are ordered accord-
ing to the i r doses, and the doses are summed i n th is order. 
Each pat ient is then assigned a rank equal to the percenti le 
o f the "co l lect ive dose" that corresponds to his pos i t i on . I f 
dose propor t i ona l i t y were to apply, the percentiles for the 
patients w i t h bone sarcoma w o u l d have to be u n i f o r m l y 
d is t r ibuted between 0 and 1. I f the dependence o n dose 
were steeper t h a n p r o p o r t i o n a l i t y there w o u l d be a t en -
dency for higher percentile values o f the bone sarcoma pa-
tients. 
Aga in the analysis is compl icated by the fact tha t each 
pat i en t w h o has i n cu r r ed a bone sarcoma needs to be 
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FIG. 7. Correlation diagrams for the relative ranks in treatment duration and age at treatment. Each patient with bone sarcoma is ranked with 
patients whose doses do not differ by more than ±25%). 
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group contains those patients who were sti l l at risk at a t ime 
after t reatment equal to the t ime to the bone sarcoma, and 
w h o had a t r ea tment d u r a t i o n tha t differs by less t h a n 
±25%. Accord ing ly one establishes for each pat ient, /c, w i t h 
a bone sarcoma a compar ison group, and the patient is 
assigned the percentile value, i.e., the relative rank, rk, i n 
collective dose, i n his compar ison group: 
CONSTANT T IN THE BANDS (+ 25%) 
R = 0.536 ALL BONE SARCOMAS 
rk = ( 2 Dj + Dkl2)IDz. 
Dj<Dk 
( 3 ) 
Dk is the dose received by the pat ient w i t h bone sarcoma, 
the Z ) 2 is the sum o f al l doses i n the compar ison group. I f 
the n u l l hypothesis holds, i.e., i f the probab i l i t y to incur a 
bone sarcoma is p r o p o r t i o n a l t o dose, the values o f rk 
should be un i f o rm l y d is t r ibuted between 0 and 1, i.e., they 
should have expectation value 0.5 and variance a2 = 1/12. 
I n actual i ty only discrete values o f rk w i t h i n the interva l 
f r o m 0 to 1 are possible that depend on the dose values Dj i n 
the group. This dev iat ion f r om the u n i f o r m d i s t r ibu t i on 
does not change the expectation value 0.5 under the n u l l 
hypothesis, but i t causes a slight decrease o f the variance 
(see A p p e n d i x ) . 
The test statistic is, as i n the previous section, the mean o f 
the values rk for al l the patients w i t h bone sarcoma, and this 
statistic, too, has the expectation value 0.5 under the n u l l 
hypothesis that the bone-sarcoma incidence is p ropor t i ona l 
to dose. 
The same test is also appl ied to examine the second hy-
pothesis, i.e., that o f dose propor t i ona l i t y at constant dose 
rates, D/r. For each sarcoma a compar ison group is estab-
lished w i t h those patients who were at risk for a sufficiently 
l ong dura t i on and who do not differ by more than the same 
fract ion ±25% i n their dose rate, D/r. The rank assigned to 
each patient w i t h bone sarcoma is obtained w i t h the same 
expression as i n Eq. ( 3 ) . 
The results are given i n Figs. 8 and 9 for the t w o tests, one 
w i t h comparison groups o f the same treatment dura t i on , r , 
and one w i t h compar ison groups o f the same dose rates, 
D/r. The tests show that l inear i ty in dose for constant r 
cannot be rejected. L inear i ty i n dose for constant D/r is 
rejected at the high level o f significance o f 0.002. 
One concludes that the data are d is t inct ly at variance 
w i t h the assumption o f dose propor t i ona l i t y under the con-
d i t i o n that exposure t ime , i.e., t reatment dura t i on , is pro-
por t i ona l to dose. Unde r this cond i t i on there is a steeper 
than l inear increase o f the bone-sarcoma incidence w i t h 
mean skeletal dose. O n the other hand, one finds that the 
data are consistent w i t h the assumption o f s imple dose pro-
por t i ona l i t y for constant exposure t imes. O n the basis o f 
these conclusions one can go a step further and ask for the 
quant i ta t ive dependence o f the bone-sarcoma incidence on 
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FIG. 8. The relative ranks in "cohort dose" of the patients with bone 
sarcoma. The results are obtained by comparison to patients whose injec-
tion durations do not differ by more than ±25%. Top: Relative ranks in 
cohort dose versus treatment durat ion. The mean relative rank is R 
= 0.536, which is in agreement with dose proportionality. The standard 
deviation of/? under the null hypothesis is 0.031. Bottom: Sum distribu-
tion of the relative ranks. 
A N A L Y S I S I N T E R M S OF A N E X T E N D E D 
PROPORT IONAL H A Z A R D S M O D E L 
O u r earlier analysis o f the 2 2 4 R a data was based o n a pro-
por t i ona l hazards mode l (8). Such a mode l impl ies that the 
t i m e dependence o f the appearance o f the bone sarcomas 
after in ject ion does not depend on the other parameters 
such as dose. Th is premise appears to apply very wel l to the 
2 2 4 R a data. I n our analysis we had considered on ly the pa-
rameter dose, and accordingly the cumulat i ve rate o f bone 
sarcoma was given by the expression 
R(t,D) = Ro{t)-f(D). ( 4 ) 
Th i s led to a l inear-quadrat ic dependence o f the bone sar-
coma incidence on mean skeletal dose. The analysis was 
not a imed at a separation o f the influences o f dose and 
t reatment dura t i on , and on the basis o f the present results 
one must conclude that the dev iat ion f r o m l ineari ty is due 
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C O N S T A N T D / T I N T H E B A N D S ( + 2 5 % ) 
R = 0 . 6 2 
which is the longest time elapsed between treatment and the 
occurrence of a bone tumor. 
The influence of the different terms of Eq. (6) on the 
quality of the maximum likelihood fit can be judged from 
the results that are listed in Table I I I . The poorest value of 
the likelihood is obtained with a mere linear fit. The result-
ing coefficient a is close to the value obtained in the earlier, 
simple linear analysis (6, 7). The utilization of the addi-
tional parameter /?, under exclusion of 7, improves the like-
lihood. However, a substantially better likelihood results i f 
the quadratic term in dose is omitted and the dependence 
(1 4- yr) is used instead. There is virtually no further in-
crease of the likelihood i f the quadratic term in dose is intro-
duced in addition to the factor (1 4- 77-); the very small 
positive value of ß can therefore be disregarded, and the 
resulting optimum fit is 
with 
R{t,D,r) = R0{t)-a-D.(\ + 7 T ) 
a = 0.0055/Gy and 7 = 0.18/month. 
(7) 
R E L A T I V E R A N K I N C U M U L A T E D D O S E 
FIG. 9. The relative ranks in "cohort dose1' of the patients with bone 
sarcoma. The results are obtained by comparison to patients whose "mean 
dose rates." Df r, do not differ by more than ±25%. Top: Relative ranks in 
cohort dose versus mean dose rate, D/T. The mean relative rank is R 
= 0.62, which is inconsistent with dose proportionality. The standard de-
viation of R under the null hypothesis is 0.043. Bottom: Sum distribution 
of the relative ranks. 
The nonparametric dependence R0(t), i-e», the distribu-
tion of bone sarcomas in time after treatment, was found to 
be largely independent of the particularities of the model, 
and the form obtained in the fit of the data to Eq. (7) (Fig. 
10) is virtually identical to the dependence obtained in the 
earlier analyses (6\ 9), which did not account for the role of 
the exposure duration. 
The integrated risk over the entire expression time is 
to the increase, on average, of the treatment durations with 
increasing injected activities, i.e., with increasing doses. 
To quantify the dependence of the bone-sarcoma rate on 
dose and exposure time, one must include the variable r, 
i.e., the treatment span, in the proportional hazards analy-
sis. For this purpose different analytical expressions were 
examined within a general proportional hazards model, i.e., 
the following dependence for the cumulative bone-sarcoma 
rate, at time t after exposure was considered: 
R(t,D,T) = R0(t)'f(D)-g(r). (5) 
A simple expression that led to a satisfactory fit was 
R(t9 Dy r) = R0(t)-(aD + ßD2)-( 1 4- yr). (6) 
R0(t) is the time dependence of the cumulative incidence, 
normalized to 1 at the end of the expression period. The 
duration of the expression period is set equal to 33 years, 
TABLE I I I 
Maximum Likelihood Analysis in Terms of Eq. (5) 
R((, D) = R0(t)-aD: 
a = 0.017/Gy 
Max.Log - Likelihood: 
R(t. D) = R0{t)-(aD + ßD2): 
cx = 0.010 Gy, 
Max.Log - Likelihood: 
-246.9 
ß = 0.00065/Gy2 
L = -244.8 
R(t, D, T) = R0(t)-aD-(\ 
a = 0.0055/Gy, 
Max.Log - Likelihood: 
yr): 
7 = 0.18/month 
L = -242.2 
R(l, D, r ) = R0(t)-(aD + ßD2)*{\ + yr): 
a - 0.0056/Gy. ß = 1.6. 10" 4/Gy 2, 
Max.Log - Likelihood: L = -242.2 
R(t, D, r, a) = R0(()'aD-(\ + yt)-ß(a) 
a = 0.0051 /Gy, 7 = 0.13/month, 
a0 = 20 years 
Max.Log - Likelihood L = -242.1 
7 = 0.16/month 
ß = 1.48 
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R(D, r) = aD( \ + yr) 
with the values a and 7 that are listed above. 
This relationship is equivalent to 




where p = D/T is the dose rate. 
One obtains, therefore, linear dose dependences (Eq. 
(8)) for constant values of r, and linear-quadratic depen-
dences (Eq. (9)) for constant dose rates, D/T. This is exem-
plified in Fig. 11, which gives the dose dependences for two 
values each of r and of D/r, that are in the range of typical 
values for the patients injected with 2 2 4 Ra. 
The general trend among the cohort of patients is closer 
to the situation of constant D/T than of constant r. This 
explains the effectively linear-quadratic dose dependence 
inferred in the earlier analyses (8, 9). In actuality, however, 
one deals with an intermediate situation. 
The nonparametric analysis had indicated, but not on a 
level of statistical significance, a higher occurrence of bone 
sarcomas at equal doses for the younger patients. To quan-
tify this observation the parametric analysis was extended 
to include the parameter age at injection. Since the present 
analysis uses an approximative and somewhat uncertain 
relationship between the injected activity and the mean skel-
etal dose, it would not be justified to use anything but a 
simple model. Equation (7) was therefore modified to 
R(t, r, a) = R0(t)-a-D-( \ + yr)-ß(a) (10) 
with 
/8(a) 
'ß for a ^ a0 
1 for a > a0. 
One obtains the value ß = 1.5 (Table I I I ) . This indicates, in 
agreement with the preceding analysis, an increased sensi-
R (t) 
TIME A F T E R 1st INJECTION ( Y E A R S ) 
FIG. 10. The cumulative distribution. # 0 (0<o fbone sarcomas in time 
that results from the maximum likelihood fit of Eq. (7) to all bone sarcoma 
data. The steps of the function occur at those times after treatment when 
bone sarcomas were diagnosed. 
R ( D , T ) -
x = 2 0 months 
D / T = 0 . 5 Cy/month 
D / T = 1 . 5 Gy/month 
2 0 
MEAN S K E L E T A L DOSE ( C y ) 
FIG. Bone sarcoma expectation, R ( D , T ) , over the entire expres-
sion period, according to Eqs. (8) and (9) . The full curves represent, ac-
cording to Eq. (8 ) , the risk for constant exposure durations r = 5 months 
and r = 20 months. The broken curves correspond to constant values D/T 
= 0.5 Gy/month and D/T = 1.5 Gy/month. 
tivity at younger age; however, ß does not differ from 1 with 
statistical significance. 
CONCLUSIONS 
A reverse protraction factor for bone sarcomas induced 
by 2 2 4 Ra had first been suggested in animal experiments 
(70) and it was subsequently inferred also for the patients 
injected with 2 2 4 Ra (5) . 
The latter conclusion, however, remained somewhat ten-
tative, because the numerical evaluation was based on a 
number of approximations. The present analysis employs 
more rigorous mathematical techniques that confirm and 
quantify the earlier conclusions by Spiess and Mays. 
Among the cohort of patients there is a broad variation of 
injected activities and of the resulting mean skeletal doses. 
This variation reflects partly the reduction of dosages dur-
ing the years, when harmful effects due to the 2 2 4 Ra treat-
ment began to be recognized. On average the larger doses 
were given in a larger number of fractions over longer pe-
riods of time, up to a maximum of 2.5 years. Even at the 
same mean skeletal doses there is, however, a broad range 
of treatment spans. This broad variation of doses and of 
treatment spans, the nearly complete follow-up, and the 
absence of an appreciable spontaneous bone-tumor rate 
have permitted the assessment of the separate influence of 
dose and treatment duration that has been the objective of 
this study. 
On the basis of the present results it is concluded that the 
seemingly linear-quadratic dependence that had earlier 
been inferred is, in fact, the combined result of proportional-
ity of the bone-sarcoma incidence on dose at constant ex-
posure time and of an increase of the incidence with longer 
exposure times at specified dose. For instance, the inci-
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dence is roughly doubled when the exposure is protracted 
over 15 months instead of being given in 5 months. 
The notable result of these interdependences is a linear 
dose relationship for constant exposure time, and a linear-
quadratic relationship for exposures with constant dose rate 
or with treatment durations proportional to dose in a frac-
tionated exposure. The result has evident implications for 
considerations of radiation protection with regard to inter-
nal a emitters. 
The observation of a reverse protraction factor for 
densely ionizing radiation is in line with a number of earlier 
experimental findings that suggest the possibility o f en-
hanced effects of densely ionizing radiations in protracted 
or fractionated exposures (10-14) . In human studies analo-
gous relationships have been seen in uranium miners ex-
posed to high levels of radon (75, 17) and recently also in 
t in miners (18). The present finding appears, therefore, to 
support and to extend earlier observations. One should, 
however, note important differences between miners and 
2 2 4 Ra patients. Uranium miners are exposed to radon and 
its daughter products over a period of several or many 
years; the durations of exposure in the 2 2 4 Ra patients vary 
from months to about 2.5 years. Furthermore the time dis-
tribution of the appearance of the bone tumors is well de-
fined, while that of the lung cancers includes an uncertain 
extrapolation in time. Moreover for the miners of the Colo-
rado plateau it was estimated that the risk increases by 10% 
i f the same exposure is protracted over 20 years rather than 
2 years; the increases inferred in the present study are sub-
stantially larger. One must further note that the conclusions 
drawn with regard to the miners may be linked to complexi-
ties of the relative risk models that are still insufficiently 
understood, such as the reduction of the relative risk with 
time after exposure, as it has been inferred for the British 
ankylosing spondylitis patients (19), and as it has been pos-
tulated for the uranium miners by the BEIR V commit-
tee (20). 
The main result of the present study is the reverse dose-
rate dependence. However, in agreement with the earlier 
suggestions by Spiess and Mays, there is also an indication 
of increased sensitivity at younger ages. But the observation 
does not reach statistical significance. We feel that the issue 
could be settled only on the basis of a better assessment of 
the dose to the skeleton, or specifically to the endosteal 
layer, per unit of activity injected at different ages. 
In the present analysis there is no indication that the re-
verse time factor applies only to the larger doses. Neverthe-
less it must be noted—and this is a further difference from 
the epidemiological studies of lung cancer in miners—that 
the data relate generally to high doses to the critical tissue 
that resulted from a past practice of 2 2 4 Ra therapy. The 
actual dose to the endosteal cells is several times larger than 
the mean skeletal dose, and even the individual injections 
of up to about 3 MBq of 2 2 4 Ra were therefore sufficient to 
cause several traversals of a particles per endosteal cell. It is 
evident that under such conditions a 'saturation effect' can 
occur for short time exposures. It is also conceivable that 
the initial fractions of a treatment induce cell proliferation 
that makes the endosteal layer more sensitive to later frac-
tions. An extrapolation of the present findings to the much 
smaller doses that are relevant under the normal conditions 
of radiation protection must therefore remain tentative and 
cannot be supported by the present data. 
A comparison of the results to the present low-dose ther-
apy for ankylosing spondylitis with 2 2 4 Ra is somewhat less 
tenuous. The treatment consists in general of 10 weekly 
injections of about 1 MBq (28 juCi) of 2 2 4 Ra, and the mean 
skeletal dose for an adult of 70-kg body weight is then esti-
mated to be 0.56 Gy. Entering this dose and r = 3 months 
into Eq. (8) , one infers a bone tumor risk of slightly less 
than 0.005 for the current treatment with low doses of 
2 2 4 Ra. This agrees with our previous estimate in terms of the 
linear-quadratic dependence (8, 9) that was reduced by a 
factor of 2 at low doses in comparison to the estimate from 
a simple linear model (6, 7). The follow-up of the patients 
for the low-dose treatment with 2 2 4 Ra is still incomplete 
(21), but it does not, up to now, suggest bone-sarcoma risks 
in excess of our present estimate. 
A P P E N D I X 
Formulae for the Variance of the Ranks 
In the tests one uses only certain discrete values of the 
relative ranks, r,, rather than the continuous variable that is 
uniformly distributed between 0 and 1 under the null hy-
pothesis. In the simple, unweighted form of the test (see 
The Presence of a Protraction Factor) the discrete values r, 
= (i - 0.5)/N correspond to the 'slices' r, ± Ar/2 of the 
uniform distribution, with Ar = 1 /N. In the weighted test 
(see Exploration of the Nature of the Dependence on Dose 
and Treatment Duration) Ar, = £>,•/D2. 
A 'randomization' of the tests, which transforms the dis-
crete statistic to the uniformly distributed statistic, replaces 
each value r, by the associated slice of the uniform distribu-
tion. Each slice is symmetrical around its central value, r,-; 
accordingly the transformation does not change the mean 
value. The discrete statistics therefore has, under the null 
hypothesis, the same mean value, 0.5, as the continuous 
uniform distribution between 0 and 1. 
The variance of the discrete statistic has the value 
a 2 = | l - 2 A^ j/12 (A . l ) 
under the null hypothesis, as can most readily be shown by 
a comparison between the contribution, bmh to the second 
moment of the discrete value r, and the contribution, Am,, 
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o' itsassociated slice i n the u n i f o r m d i s t r i bu t i on . The proba-
b.lity o f the value r, i n the discrete d i s t r i bu t i on and the 
probab i l i t y i n the c o n t i n u o u s u n i f o r m d i s t r i b u t i o n o f a 
value w i t h i n the slice are bo th equal to Ar , . 
Accord ing ly one has the cont r ibut ions to the second m o -
ment, 
8mj = rj • Ar , 
Ami = x2dx = r] • Ar,- + Ar)112. (A .2 ) 
J r,- Arr/2 
Summing a l l terms, one concludes that the second m o m e n t 
of the con t inuous u n i f o r m d i s t r i bu t i on between 0 and 1 
exceeds the second m o m e n t o f the discrete d i s t r i bu t i on by 
2 £ i Ar) 112. The mean values o f the two d is t r ibut ions are 
equal. The difference o f the i r variances equals, therefore, 
the difference o f the second moments . Since the variance o f 
the u n i f o r m d i s t r i bu t i on is 1/12, one obtains Eq. ( A . l ) . 
For Ar , = 1 /N Eq. (A . 1) reduces to the more fami l iar for-
mula <r2 = (1 - I/TV 2 )/12. 
The variance o f the sum o f F r a n k s equals the sum o f the 
variances o f the i nd i v i dua l ranks. Th is determines the var i -
ances o f the average ranks. 
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